Gynecologic Cancer clinical trials

Explore recruiting gynecologic cancer clinical trials.

Recruiting gynecologic cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gynecologic Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

Italy, Norway, Spain, France, Denmark, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

Belgium, Italy, France, Hungary, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Denmark, Norway, Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum- Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer

Spain, Norway, Czechia, Netherlands, Germany, Belgium +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)

Spain, Czechia, France, Belgium, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Gynecologic Cancer trials by city

Gynecologic Cancer in Toronto Gynecologic Cancer in Vancouver Gynecologic Cancer in Montreal Gynecologic Cancer in Calgary Gynecologic Cancer in Edmonton Gynecologic Cancer in Ottawa Gynecologic Cancer in Winnipeg Gynecologic Cancer in Quebec City Gynecologic Cancer in Hamilton Gynecologic Cancer in Kitchener Gynecologic Cancer in London Gynecologic Cancer in Halifax Gynecologic Cancer in New York Gynecologic Cancer in Los Angeles Gynecologic Cancer in Chicago Gynecologic Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease